Tislelizumab Clinical Trials (97 Recruiting)

Showing 1–20 of 105 trials

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Advanced Solid TumorSolid Tumor

BeOne Medicines217 enrolled27 locationsNCT05981703

Recruiting

Phase 2

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC)Neoadjuvant TherapyHead and Neck Squamous Cell Carcinoma+1 more

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine182 enrolled1 locationNCT07601737

Recruiting

Phase 1Phase 2

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Non-small Cell Lung CancerPancreatic Ductal Adenocarcinoma

Phanes Therapeutics40 enrolled6 locationsNCT05431270

Recruiting

Phase 2

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Colorectal, CancerMinimal Residual DiseasectDNA+3 more

M.D. Anderson Cancer Center20 enrolled1 locationNCT07136077

Recruiting

Phase 1

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

Metastatic Hepatocellular CarcinomaLocal Advanced Hepatocellular CarcinomaAlpha-fetoprotein (AFP)-Producing Gastric Cancer+2 more

BeOne Medicines392 enrolled29 locationsNCT06427941

Recruiting

Phase 2

A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

Esophageal Squamous Cell CarcinomaAdvanced Unresectable Gastric AdenocarcinomaAdvanced Gastroesophageal Adenocarcinoma

BeOne Medicines30 enrolled1 locationNCT07554521

Recruiting

Phase 1

Intranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC

HPV Positive Oropharyngeal Squamous Cell Carcinoma

West China Hospital9 enrolled1 locationNCT07565740

Recruiting

Phase 2

A Study of SKB518 in Patients With Lung Cancer

Lung Carcinoma

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.192 enrolled17 locationsNCT07019675

Recruiting

Phase 3

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

NSCLC Stage IV

ImmunityBio, Inc.507 enrolled19 locationsNCT06745908

Recruiting

Phase 2

Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma

Biliary Tract Carcinoma

Suzhou Zelgen Biopharmaceuticals Co.,Ltd60 enrolled1 locationNCT07099547

Recruiting

Phase 1

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

Solid Tumor

Sichuan University24 enrolled1 locationNCT06349837

Recruiting

Phase 2

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

CholangiocarcinomaBile Duct CancerHilar Cholangiocarcinoma

Jinbo Yue38 enrolled1 locationNCT07030140

Recruiting

Phase 2

A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.

Head and Neck Squamous Cell CarcinomaTargeted TherapyImmunotherapy+1 more

West China Hospital98 enrolled1 locationNCT07040956

Recruiting

Phase 1Phase 2

Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy

Rectal Cancer

Fudan University50 enrolled1 locationNCT07561060

Recruiting

Phase 2

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

Extensive-stage Small-cell Lung Cancer

Second Hospital of Shanxi Medical University40 enrolled6 locationsNCT06536868

Recruiting

Phase 3

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

Urothelial Carcinoma

BeiGene420 enrolled46 locationsNCT03967977

Recruiting

Phase 1

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

Advanced Solid Tumor

BeOne Medicines308 enrolled38 locationsNCT06233942

Recruiting

Phase 2

Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure

NSCLC (Advanced Non-small Cell Lung Cancer)NSCLC (Non-small Cell Lung Cancer)

Tianjin Medical University Cancer Institute and Hospital20 enrolled1 locationNCT07528274

Tislelizumab Clinical Trials

A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors

A Study of BG-C477 in Participants With Advanced Solid Tumors

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

Intranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC

A Study of SKB518 in Patients With Lung Cancer

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.

Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure